MersV1, Main, Exploration, bibRecord, 003A79

Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen

Identifieur interne : 003A79 ( Main/Exploration ); précédent : 003A78; suivant : 003A80

Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen

Auteurs : Lawrence Corey [États-Unis] ; M. Juliana Mcelrath [États-Unis] ; Kent Weinhold [États-Unis] ; Thomas Matthews [États-Unis] ; Donald Stablein [États-Unis] ; Barney Graham [États-Unis] ; Michael Keefer [États-Unis] ; David Schwartz [États-Unis] ; Geoffrey Gorse [États-Unis]

Source :

Journal of Infectious Diseases [ 0022-1899 ] ; 1998.

RBID : ISTEX:D94B9FA8C67707643C68CBF9D95B00F186D8F2D7

Abstract

Effective human immunodeficiency virus (HIV) vaccination may require induction of neutralizing antibodies (NAs) and CD8+ cytotoxic T lymphocytes (CTL) to prevent transmission and control early infection. Recombinant envelope proteins induce NAs but rarely CD8/ CTL responses, and vaccinia vectors containing HIV-1 envelope elicit CD8/ cytotoxicity but few NAs. To benefit from both approaches, 56 vaccinia-naive subjects were randomized to a regimen of priming with recombinant vaccinia gp160LAI and boosting with recombinant gp120SF-2, gp120LAI, gp120MN, or gp160MN. Of 51 persons for whom assays were done, 26 demonstrated envelope-specific CTL. Boosting with gp120, compared with gp160, elicited significantly more NAs and CD4-blocking antibodies. Neutralization of the homologous and heterologous HIV-1 laboratory strains occurred in all subjects receiving vac/env and gp120 and was detectable in 91% of the subjects for < 6 months. Thus, vaccine regimens in which one component elicits primarily CTL and the other NAs offer promise for the development of an effective HIV-1 vaccine strategy.

Url:

https://api.istex.fr/ark:/67375/HXZ-S123M5TF-G/fulltext.pdf

DOI: 10.1086/514202

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 001D51
to stream Istex, to step Curation: 001D51
to stream Istex, to step Checkpoint: 001288
to stream Main, to step Merge: 003B28
to stream Main, to step Curation: 003A79

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen</title>
<author><name sortKey="Corey, Lawrence" sort="Corey, Lawrence" uniqKey="Corey L" first="Lawrence" last="Corey">Lawrence Corey</name>
</author>
<author><name sortKey="Mcelrath, M Juliana" sort="Mcelrath, M Juliana" uniqKey="Mcelrath M" first="M. Juliana" last="Mcelrath">M. Juliana Mcelrath</name>
</author>
<author><name sortKey="Weinhold, Kent" sort="Weinhold, Kent" uniqKey="Weinhold K" first="Kent" last="Weinhold">Kent Weinhold</name>
</author>
<author><name sortKey="Matthews, Thomas" sort="Matthews, Thomas" uniqKey="Matthews T" first="Thomas" last="Matthews">Thomas Matthews</name>
</author>
<author><name sortKey="Stablein, Donald" sort="Stablein, Donald" uniqKey="Stablein D" first="Donald" last="Stablein">Donald Stablein</name>
</author>
<author><name sortKey="Graham, Barney" sort="Graham, Barney" uniqKey="Graham B" first="Barney" last="Graham">Barney Graham</name>
</author>
<author><name sortKey="Keefer, Michael" sort="Keefer, Michael" uniqKey="Keefer M" first="Michael" last="Keefer">Michael Keefer</name>
</author>
<author><name sortKey="Schwartz, David" sort="Schwartz, David" uniqKey="Schwartz D" first="David" last="Schwartz">David Schwartz</name>
</author>
<author><name sortKey="Gorse, Geoffrey" sort="Gorse, Geoffrey" uniqKey="Gorse G" first="Geoffrey" last="Gorse">Geoffrey Gorse</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D94B9FA8C67707643C68CBF9D95B00F186D8F2D7</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1086/514202</idno>
<idno type="url">https://api.istex.fr/ark:/67375/HXZ-S123M5TF-G/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001D51</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001D51</idno>
<idno type="wicri:Area/Istex/Curation">001D51</idno>
<idno type="wicri:Area/Istex/Checkpoint">001288</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001288</idno>
<idno type="wicri:doubleKey">0022-1899:1998:Corey L:cytotoxic:t:cell</idno>
<idno type="wicri:Area/Main/Merge">003B28</idno>
<idno type="wicri:Area/Main/Curation">003A79</idno>
<idno type="wicri:Area/Main/Exploration">003A79</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen</title>
<author><name sortKey="Corey, Lawrence" sort="Corey, Lawrence" uniqKey="Corey L" first="Lawrence" last="Corey">Lawrence Corey</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Infectious Diseases Program, University of Washington School of Medicine, Seattle, Washington, Durham, North Carolina, Nashville, Tennessee, Rochester, New York, Baltimore, Bethesda, Maryland, St. Louis</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
<wicri:cityArea>Reprints or correspondence: Dr. Lawrence Corey, 1124 Columbia St. (M115), Seattle</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mcelrath, M Juliana" sort="Mcelrath, M Juliana" uniqKey="Mcelrath M" first="M. Juliana" last="Mcelrath">M. Juliana Mcelrath</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Infectious Diseases Program, University of Washington School of Medicine, Seattle, Washington, Durham, North Carolina, Nashville, Tennessee, Rochester, New York, Baltimore, Bethesda, Maryland, St. Louis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Weinhold, Kent" sort="Weinhold, Kent" uniqKey="Weinhold K" first="Kent" last="Weinhold">Kent Weinhold</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Infectious Diseases Program, University of Washington School of Medicine, Seattle, Washington, Durham, North Carolina, Nashville, Tennessee, Rochester, New York, Baltimore, Bethesda, Maryland, St. Louis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Matthews, Thomas" sort="Matthews, Thomas" uniqKey="Matthews T" first="Thomas" last="Matthews">Thomas Matthews</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Infectious Diseases Program, University of Washington School of Medicine, Seattle, Washington, Durham, North Carolina, Nashville, Tennessee, Rochester, New York, Baltimore, Bethesda, Maryland, St. Louis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Stablein, Donald" sort="Stablein, Donald" uniqKey="Stablein D" first="Donald" last="Stablein">Donald Stablein</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Infectious Diseases Program, University of Washington School of Medicine, Seattle, Washington, Durham, North Carolina, Nashville, Tennessee, Rochester, New York, Baltimore, Bethesda, Maryland, St. Louis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Graham, Barney" sort="Graham, Barney" uniqKey="Graham B" first="Barney" last="Graham">Barney Graham</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Infectious Diseases Program, University of Washington School of Medicine, Seattle, Washington, Durham, North Carolina, Nashville, Tennessee, Rochester, New York, Baltimore, Bethesda, Maryland, St. Louis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Keefer, Michael" sort="Keefer, Michael" uniqKey="Keefer M" first="Michael" last="Keefer">Michael Keefer</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Infectious Diseases Program, University of Washington School of Medicine, Seattle, Washington, Durham, North Carolina, Nashville, Tennessee, Rochester, New York, Baltimore, Bethesda, Maryland, St. Louis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Schwartz, David" sort="Schwartz, David" uniqKey="Schwartz D" first="David" last="Schwartz">David Schwartz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Infectious Diseases Program, University of Washington School of Medicine, Seattle, Washington, Durham, North Carolina, Nashville, Tennessee, Rochester, New York, Baltimore, Bethesda, Maryland, St. Louis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gorse, Geoffrey" sort="Gorse, Geoffrey" uniqKey="Gorse G" first="Geoffrey" last="Gorse">Geoffrey Gorse</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Infectious Diseases Program, University of Washington School of Medicine, Seattle, Washington, Durham, North Carolina, Nashville, Tennessee, Rochester, New York, Baltimore, Bethesda, Maryland, St. Louis</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Journal of Infectious Diseases</title>
<title level="j" type="abbrev">J Infect Dis.</title>
<idno type="ISSN">0022-1899</idno>
<idno type="eISSN">1537-6613</idno>
<imprint><publisher>The University of Chicago Press</publisher>
<date type="published">1998</date>
<biblScope unit="vol">177</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="301">301</biblScope>
<biblScope unit="page" to="309">309</biblScope>
</imprint>
<idno type="ISSN">0022-1899</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0022-1899</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Effective human immunodeficiency virus (HIV) vaccination may require induction of neutralizing antibodies (NAs) and CD8+ cytotoxic T lymphocytes (CTL) to prevent transmission and control early infection. Recombinant envelope proteins induce NAs but rarely CD8/ CTL responses, and vaccinia vectors containing HIV-1 envelope elicit CD8/ cytotoxicity but few NAs. To benefit from both approaches, 56 vaccinia-naive subjects were randomized to a regimen of priming with recombinant vaccinia gp160LAI and boosting with recombinant gp120SF-2, gp120LAI, gp120MN, or gp160MN. Of 51 persons for whom assays were done, 26 demonstrated envelope-specific CTL. Boosting with gp120, compared with gp160, elicited significantly more NAs and CD4-blocking antibodies. Neutralization of the homologous and heterologous HIV-1 laboratory strains occurred in all subjects receiving vac/env and gp120 and was detectable in 91% of the subjects for < 6 months. Thus, vaccine regimens in which one component elicits primarily CTL and the other NAs offer promise for the development of an effective HIV-1 vaccine strategy.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Missouri (État)</li>
<li>Washington (État)</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Missouri (État)"><name sortKey="Corey, Lawrence" sort="Corey, Lawrence" uniqKey="Corey L" first="Lawrence" last="Corey">Lawrence Corey</name>
</region>
<name sortKey="Corey, Lawrence" sort="Corey, Lawrence" uniqKey="Corey L" first="Lawrence" last="Corey">Lawrence Corey</name>
<name sortKey="Gorse, Geoffrey" sort="Gorse, Geoffrey" uniqKey="Gorse G" first="Geoffrey" last="Gorse">Geoffrey Gorse</name>
<name sortKey="Graham, Barney" sort="Graham, Barney" uniqKey="Graham B" first="Barney" last="Graham">Barney Graham</name>
<name sortKey="Keefer, Michael" sort="Keefer, Michael" uniqKey="Keefer M" first="Michael" last="Keefer">Michael Keefer</name>
<name sortKey="Matthews, Thomas" sort="Matthews, Thomas" uniqKey="Matthews T" first="Thomas" last="Matthews">Thomas Matthews</name>
<name sortKey="Mcelrath, M Juliana" sort="Mcelrath, M Juliana" uniqKey="Mcelrath M" first="M. Juliana" last="Mcelrath">M. Juliana Mcelrath</name>
<name sortKey="Schwartz, David" sort="Schwartz, David" uniqKey="Schwartz D" first="David" last="Schwartz">David Schwartz</name>
<name sortKey="Stablein, Donald" sort="Stablein, Donald" uniqKey="Stablein D" first="Donald" last="Stablein">Donald Stablein</name>
<name sortKey="Weinhold, Kent" sort="Weinhold, Kent" uniqKey="Weinhold K" first="Kent" last="Weinhold">Kent Weinhold</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A79 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A79 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:D94B9FA8C67707643C68CBF9D95B00F186D8F2D7
   |texte=   Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen

Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri